Search results for "Platelet Aggregation"

showing 10 items of 155 documents

High-throughput elucidation of thrombus formation reveals sources of platelet function variability

2019

In combination with microspotting, whole-blood microfluidics can provide high-throughput information on multiple platelet functions in thrombus formation. Based on assessment of the inter-and intra-subject variability in parameters of microspot-based thrombus formation, we aimed to determine the platelet factors contributing to this variation. Blood samples from 94 genotyped healthy subjects were analyzed for conventional platelet phenotyping: i.e. hematologic parameters, platelet glycoprotein (GP) expression levels and activation markers (24 parameters). Furthermore, platelets were activated by ADP, CRP-XL or TRAP. Parallel samples were investigated for whole-blood thrombus formation (6 mi…

Blood PlateletsPlatelet AggregationPlatelet Function TestsDISORDERSIntegrinPlatelet Membrane GlycoproteinsADHESIONPlatelet membrane glycoproteinArticleImmunophenotypingFlow cytometry03 medical and health sciences0302 clinical medicinePlatelet Biology & Its DisordersmedicineHumansPlateletPlatelet activationThrombuschemistry.chemical_classificationmedicine.diagnostic_testbiologyPlatelet CountThrombosisHematologyFlow CytometryPlatelet Activationmedicine.diseaseDIFFERENCEHigh-Throughput Screening AssaysCell biologychemistrybiology.proteinGPVIGlycoproteinBiomarkers030215 immunologyRESPONSESHaematologica-the Hematology Journal
researchProduct

Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors

2014

Platelets are permanently exposed to a variety of prostanoids formed by blood cells or the vessel wall. The two major prostanoids, prostacyclin and thromboxane act through well established pathways mediated by their respective G-protein coupled receptors inhibiting or promoting platelet aggregation accordingly. Yet the role of other prostanoids and prostanoid receptors for platelet function regulation has not been thoroughly investigated. We aimed at a comprehensive analysis of prostanoid effects on platelets, the receptors and pathways involved and functional consequences. We analyzed cAMP formation and phosphorylation of proteins pivotal to platelet function as well as functional platelet…

Blood PlateletsSerotoninmedicine.medical_specialtyPlatelet AggregationProstaglandin E2 receptorReceptors ProstaglandinProstaglandinProstacyclinchemistry.chemical_compoundAdenosine TriphosphateP2Y12Internal medicineCyclic AMPmedicineHumansPlateletPlatelet activationReceptorMitogen-Activated Protein Kinase KinasesPharmacologyChemistryMicrofilament Proteinsrap1 GTP-Binding ProteinsProstanoidrespiratory systemPhosphoproteinsCell biologyAdenosine DiphosphateP-SelectinEndocrinologyProstaglandinscardiovascular systemCalciumlipids (amino acids peptides and proteins)Cell Adhesion Moleculesmedicine.drugEuropean Journal of Pharmacology
researchProduct

Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-trea…

1996

Abstract In previous studies conducted in rats and in women, we have shown that oral contraceptive (OC) administration induced a platelet hyperaggregation simultaneously with an increased platelet lipid biosynthesis which might be related to lipid peroxidation. In the present study, we specifically studied the arachidonic acid and the fibrinolytic pathways in relation to the fatty acid composition in female rats treated for 6 weeks with OC (ethinyl estradiol plus lynestrenol). We found that platelets of treated animals were not only hyper-responsive to thrombin and ADP, but also to sodium arachidonate. In addition, the results of the thrombin-induced release of labeled arachidonic acid pre-…

Blood Plateletsmedicine.medical_specialtyErythrocytesPlatelet AggregationThromboxaneRadioimmunoassayLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundThromboxane A2Internal medicineLipid biosynthesisThromboembolismmedicineAnimalsArachidonic AcidFibrinolysisThromboxanesUrokinase-Type Plasminogen ActivatorRecombinant ProteinsRatsThromboxane B2Disease Models AnimalOxidative StressEndocrinology12-Hydroxyheptadecatrienoic acidchemistryMacrophages Peritoneal12-Hydroxyeicosatetraenoic acidArachidonic acidFemaleLipid PeroxidationCardiology and Cardiovascular MedicineContraceptives OralAtherosclerosis
researchProduct

Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP

1995

Abstract The molecular mechanism of the synergistic platelet inhibition by activators of adenylate cyclase and guanylate cyclase in human platelets was investigated. The adenylate cyclase activators iloprost and prostaglandin E 1 and the guanylate cyclase activator 3-morpholino-synonimine (SIN-1) dose-dependently inhibited thrombin-induced aggregation of washed human platelets. Furthermore, SIN-1 at a concentration inhibiting platelet aggregation by only 10% shifted the IC 50 values of iloprost and prostaglandin E 1 by one order of magnitude to the left, indicating a synergistic action of adenylate cyclase and guanylate cyclase activators. Iloprost and prostaglandin E 1 dose-dependently ele…

Blood Plateletsmedicine.medical_specialtyGUCY1B3Platelet Aggregationmedicine.medical_treatmentAdenylate kinaseIn Vitro TechniquesNitric OxideCyclasechemistry.chemical_compoundInternal medicineCyclic AMPmedicineHumansPlateletIloprostAlprostadilCyclic GMPPharmacologyForskolinGUCY1A3PhosphodiesteraseDrug SynergismEnzyme ActivationEndocrinologychemistryGuanylate CyclaseMolsidominelipids (amino acids peptides and proteins)Platelet Aggregation InhibitorsAdenylyl CyclasesProstaglandin EEuropean Journal of Pharmacology: Molecular Pharmacology
researchProduct

Increased Platelet Sensitivity toward Platelet Inhibitors during Physical Exercise in Patients with Coronary Artery Disease

1999

Generalized atherosclerosis and coronary artery disease (CAD) are associated with endothelial dysfunction and during acute myocardial ischemia platelet activation has been reported. Activated platelets exert activated fibrinogen receptors (GP IIb/IIIa) and express CD 62p being regarded as reliable marker for platelet activation. Patients with angiographically proven CAD performed a bicycle exercise test until the onset of angina or ST-segment depression. We studied the ischemia-induced alterations in fibrinogen binding to activated platelet GP IIb/IIIa receptors and CD 62p expression. Therefore, the basal fibrinogen binding to GP IIb/IIIa and CD 62p expression and the thrombin-concentration…

Blood Plateletsmedicine.medical_specialtyMyocardial IschemiaCoronary DiseaseProstacyclinPlatelet Glycoprotein GPIIb-IIIa ComplexNitric OxideFibrinogenThrombinRisk FactorsInternal medicinemedicineHumansPlateletcardiovascular diseasesPlatelet activationEndothelial dysfunctionbusiness.industryThrombinFibrinogen bindingHematologyMiddle AgedPlatelet Activationmedicine.diseaseEpoprostenolRadiographyP-SelectinEndocrinologyExercise TestCardiologybusinessPlatelet Aggregation Inhibitorsmedicine.drugIloprostThrombosis Research
researchProduct

Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry

2017

The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians because of its frequency and the severity of adverse events related to it. The identification of patients with high platelet reactivity (HPR may help to improve their therapy applying the concept of personalized medicine, most important in the older people treated with polypharmacy. The existece of such a simple clinical method as the STIB score, that allows to predict the possible resistace to clopidogrel at the bedside without using expensive laboratory investigations, provides an attractive approach to the problem.

Blood Plateletsmedicine.medical_specialtyTiclopidineSettore MED/09 - Medicina InternaHPRTreatment outcomeMEDLINEClopidogrel resistance030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinePrevalenceInternal MedicinemedicineClopidogrel resistance HPR STIB score REPOSIHumansIn patientPlateletRegistriesSTIB score030212 general & internal medicineTiclopidineClopidogrel resistance; HPR; REPOSI; STIB score; Internal Medicinebusiness.industryClopidogrel resistanceREPOSISurgeryTreatment OutcomePlatelet aggregation inhibitorbusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.

2014

Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1 modify effect of such dose-adjustment strategy.Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off value of ≥60% was defined as hyporesponsiveness. Polymorphism of two cytochromes (CYP2C19, CYP2C9) and gene ABCB1 were determined. …

CYP2C9MaleMedicine (General)ATP Binding Cassette Transporter Subfamily BTiclopidinemedicine.medical_treatmentCYP2C19PharmacologyR5-920Percutaneous Coronary InterventionmedicinePotencyHumansProspective StudiesCYP2C19AlleleCYP2C9AllelesAgedCytochrome P-450 CYP2C9Medicine(all)Polymorphism GeneticDose-Response Relationship Drugbusiness.industryClopidogrel resistanceMicrofilament ProteinsPercutaneous coronary interventionABCB1Drug-Eluting StentsVASPMiddle AgedClopidogrelPhosphoproteinsClopidogrelCytochrome P-450 CYP2C19Drug-eluting stentPharmacogeneticsAutomotive EngineeringConventional PCIFemalebusinessCell Adhesion MoleculesPlatelet Aggregation InhibitorsClopidogrel resistance; VASP; CYP2C19; ABCB1; CYP2C9medicine.drugMedicina (Kaunas, Lithuania)
researchProduct

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy

2019

AbstractThe most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60%…

Carotid Artery DiseasesMaleRisk0301 basic medicinemedicine.medical_specialtyCardiologyHemorrhageThromboembolic stroke030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineRivaroxabanCarotid artery diseaseInternal medicineIschaemic strokeMyocardial RevascularizationmedicineHumansAgedAspirinbusiness.industryIncidence (epidemiology)Atherosclerotic diseaseAnticoagulantsAtrial fibrillationHematologyMiddle AgedAtherosclerosismedicine.diseaseClopidogrelReview articleCarotid Arteries030104 developmental biology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCardiovascular Diseasesanti-platelet; anti-thrombotic therapy; anticoagulant; aspirin; carotid artery disease; rivaroxabanCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessPlatelet Aggregation InhibitorsThrombosis and Haemostasis
researchProduct

Gas chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations

1998

Resveratrol is a trihydroxystilbene present in certain red wines. It may play a role in the inhibition of lipoprotein oxidation and platelet activity. We have developed the first method to measure resveratrol in animal and human samples and to study its incorporation in vitro. After adding epicoprostanol as an internal standard, samples are subjected to lipid extraction in the presence of antioxidant and under dim light to minimize both denaturation and isomerization of the trans-resveratrol to the cis-form. Extracts were purified by cold acetone precipitation and the resveratrol-containing acetone phase was evaporated under nitrogen. The resveratrol was analyzed as a trimethylsilyl derivat…

Chromatography GasErythrocytesAntioxidantendocrine system diseasesmedicine.medical_treatmentResveratrolSensitivity and Specificitychemistry.chemical_compoundStilbenesAcetonemedicineAnimalsHumansPlatelet activationLipoprotein oxidationDetection limitChromatographyorganic chemicalsReproducibility of Resultsfood and beveragesStereoisomerismGeneral ChemistryRatsLipoproteins LDLchemistryResveratrolCalibrationLinear ModelsGas chromatographyQuantitative analysis (chemistry)Platelet Aggregation InhibitorsJournal of Chromatography B: Biomedical Sciences and Applications
researchProduct

Oral Glycoprotein IIb/IIa Antagonists for Unstable Angina — Is There Still a Chance for the Oral Substances?

2001

The intravenous glycoprotein IIb/IIIa antagonists abciximab, tirofiban and eptifibatide are well accepted for the therapy of patients with unstable angina and/or as concomitant medication during coronary interventions. Despite the fact that these drugs are not used in all patients presenting with unstable angina during coronary interventions, the scientific evidence is overwhelming including the substantial reduction in mortality 3 years after utilisation of abciximab for coronary interventions in patients with unstable angina. In addition to these two indications, intravenous glycoprotein IIb/IIIa antagonists are currently being investigated for use in patients undergoing carotid artery in…

Clinical Trials as Topicmedicine.medical_specialtyUnstable anginaFibrinogen receptorbusiness.industryAdministration OralPlatelet Glycoprotein GPIIb-IIIa ComplexHematologyTirofibanmedicine.diseaseAnginaInternal medicinemedicineAbciximabCardiologyEptifibatideHumansAngina UnstableMyocardial infarctionbusinessStrokePlatelet Aggregation Inhibitorsmedicine.drugThrombosis Research
researchProduct